Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Bridgitte E. Palacios"'
Autor:
Yanli Cheng, Zhongtian Shen, Yaqi Gao, Feilong Chen, Huisha Xu, Qinling Mo, Xinlei Chu, Chang-liang Peng, Takese T. McKenzie, Bridgitte E. Palacios, Jian Hu, Hao Zhou, Jiafu Long
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-13 (2022)
Oncoprotein SS18-SSX is a hallmark of synovial sarcoma. Here the authors report phase separation of SS18-SSX and the binding of SS18-SSX to chromatin remodeling complex are important for the transformation activity of the oncoprotein SS18-SSX.
Externí odkaz:
https://doaj.org/article/d7f20b03317d48be9aac837fe6866858
Autor:
Salvador Alejo, Bridgitte E Palacios, Prabhakar Pitta Venkata, Yi He, Wenjing Li, Jessica D Johnson, Yihong Chen, Sridharan Jayamohan, Uday P Pratap, Kyra Clarke, Yi Zou, Yingli Lv, Korri Weldon, Suryavathi Viswanadhapalli, Zhao Lai, Zhenqing Ye, Yidong Chen, Andrea R Gilbert, Takayoshi Suzuki, Rajeshwar R Tekmal, Weixing Zhao, Siyuan Zheng, Ratna K Vadlamudi, Andrew J Brenner, Gangadhara R Sareddy
Publikováno v:
Neuro-Oncology.
Background Efficient DNA repair in response to standard chemo and radiation therapies often contributes to glioblastoma (GBM) therapy resistance. Understanding the mechanisms of therapy resistance and identifying the drugs that enhance the therapeuti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::39647c00ee603152103b31858aadf034
https://doi.org/10.1093/neuonc/noad018
https://doi.org/10.1093/neuonc/noad018
Publikováno v:
J Neuroendocrinol
Demyelination results from the pathological loss of myelin and is a hallmark of many neurodegenerative diseases. Despite the prevalence of demyelinating diseases, there are no disease modifying therapies that prevent the loss of myelin or promote rem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26d2a37a2d895b95dc415499440a5e41
https://europepmc.org/articles/PMC9339486/
https://europepmc.org/articles/PMC9339486/
Autor:
Suryavathi Viswanadhapalli, Uday P. Pratap, Rajeshwar R. Tekmal, Salvador Alejo, Ratna K. Vadlamudi, Mei Zhou, Bridgitte E. Palacios, Gangadhara R. Sareddy, Zhao Lai, Junhao Liu, Yihong Chen, Yi Zou, Takayoshi Suzuki, Andrew Brenner, Prabhakar Pitta Venkata, Yi He
Publikováno v:
Breast Cancer Research and Treatment. 185:343-357
Cancer stem cells (CSCs) are highly tumorigenic, spared by chemotherapy, sustain tumor growth, and are implicated in tumor recurrence after conventional therapies in triple negative breast cancer (TNBC). Lysine-specific histone demethylase 1A (KDM1A)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a55a814c70798e45dcaa72aec052af8
https://doi.org/10.1007/s10549-020-05963-1
https://doi.org/10.1007/s10549-020-05963-1
Autor:
Yihong Chen, Prabhakar Pitta Venkata, Xiaonan Li, Kristin A. Altwegg, Suryavathi Viswanadhapalli, Mengxing Li, Gangadhara R. Sareddy, Uday P. Pratap, Yiliao Luo, Bridgitte E. Palacios, Ratna K. Vadlamudi, Andrew Brenner, Junhao Liu, Manjeet K. Rao
Publikováno v:
Mol Carcinog
Medulloblastoma (MB) is the most common and deadliest brain tumor in children. Proline-, glutamic acid-, and leucine-rich protein 1 (PELP1) is a scaffolding protein and its oncogenic signaling is implicated in the progression of several cancers. Howe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f162ece285fe3a561d8f815d4649ac4b
https://doi.org/10.1002/mc.23152
https://doi.org/10.1002/mc.23152
Autor:
Yanli Cheng, Zhongtian Shen, Yaqi Gao, Feilong Chen, Huisha Xu, Qinling Mo, Xinlei Chu, Chang-liang Peng, Takese T. McKenzie, Bridgitte E. Palacios, Jian Hu, Hao Zhou, Jiafu Long
Publikováno v:
Nature communications. 13(1)
Oncoprotein SS18-SSX is a hallmark of synovial sarcomas. However, as a part of the SS18-SSX fusion protein, SS18’s function remains unclear. Here, we depict the structures of both human SS18/BRG1 and yeast SNF11/SNF2 subcomplexes. Both subcomplexes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6abab3c593cb440052451a1c518d7b4a
https://pubmed.ncbi.nlm.nih.gov/35585082
https://pubmed.ncbi.nlm.nih.gov/35585082
Autor:
Takayoshi Suzuki, Gabrielle Gray, Rajeshwar Rao Tekmal, Yi He, Srinath Palakurthi, Sureshkumar Mulampurath Achuthan Pillai, Prabhakar Pitta Venkata, Zhao Lai, Junhao Liu, Edward R. Kost, Salvador Alejo, Suryavathi Viswanadhapalli, Ilanna Loeffel, Gangadhara R. Sareddy, Yi Zou, Bridgitte E. Palacios, Ratna K. Vadlamudi, Uday P. Pratap, Yihong Chen
Publikováno v:
Cancer letters. 524
Endometrial cancer (EC) often exhibit aberrant activation of PI3K/Akt/mTOR signaling and targeted therapies using mTOR inhibitors showed limited success. The epigenetic modifier, lysine-specific histone demethylase-1A (KDM1A/LSD1) is overexpressed in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70ad2d9424beea8ece843b299524d4ec
https://pubmed.ncbi.nlm.nih.gov/34673129
https://pubmed.ncbi.nlm.nih.gov/34673129
Autor:
Gabrielle Gray, Yihong Chen, Siyuan Zheng, GR Sareddy, Bridgitte E. Palacios, Yi He, Rajeshwar Rao Tekmal, Andrew Brenner, Uday P. Pratap, Suryavathi Viswanadhapalli, Salvador Alejo, Prabhakar Pitta Venkata
Publikováno v:
Cancer Research. 81:2026-2026
Background: Glioblastoma (GBM) is the most common malignant brain tumor with a dismal prognosis and median survival of 20 months. Standard therapy consists of surgical resection, external beam radiation therapy, adjuvant chemotherapy with temozolomid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::455a98521352d187abaa77eee73d43b1
https://doi.org/10.1158/1538-7445.am2021-2026
https://doi.org/10.1158/1538-7445.am2021-2026
Autor:
Yihong Chen, Prabhakar Pitta Venkata, Siyuan Zheng, Andrew Brenner, Uday P. Pratap, Ratna K. Vadlamudi, Gangadhara R. Sareddy, Suryavathi Viswanadhapalli, Yi He, Bridgitte E. Palacios, Salvador Alejo
Publikováno v:
Neuro Oncol
BACKGROUND Despite treatment advances, glioblastoma (GBM) is the deadliest tumor of the central nervous system. Patients face a dismal 15-month median survival and average 5-year survival rate of 13%. Current standard of care includes surgical resect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ede97f68363aae931b918cfe2b4d6dc
https://doi.org/10.1093/neuonc/noaa215.383
https://doi.org/10.1093/neuonc/noaa215.383
Autor:
Bridgitte E. Palacios, Salvador Alejo, Yi He, Takayoshi Suzuki, Kristin A. Altwegg, Gangadhara R. Sareddy, Uday P. Pratap, Rajeshwar Rao Tekmal, Edward R. Kost, Suryavathi Viswanadhapalli, Yihong Chen, Prabhakar Pitta Venkata, Ilanna Loeffel
Publikováno v:
Cancer Research. 80:1764-1764
Background: Ovarian cancer (OCa) is the deadliest gynecologic cancer. Recent studies suggest that OCa cells express estrogen receptor beta (ESR2), which functions as a tumor suppressor. However, ESR2 expression decreases during tumor progression and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1cdaa4f6450b63ea559abd7c92c6ef03
https://doi.org/10.1158/1538-7445.am2020-1764
https://doi.org/10.1158/1538-7445.am2020-1764